Trial Profile
Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study (Herhaalde toediening van rhenium-188-HEDP versus radium-223-chloride aan patienten met gemetastaseerd castratie-resistent prostaatcarcinoom; de RaRe studie. )
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Rhenium-188-etidronic acid (Primary) ; Radium 223 chloride
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms RaRe
- 18 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 28 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Clinical study design was presented at the 110th Annual Meeting of the American Association for Cancer Research.